Financings Roundup
Ariad Pads Cash with $300M For Iclusig Launch, Clinic Work
By Jennifer Boggs
Managing Editor
Managing Editor
A month after the earlier-than-expected approval of Iclusig (ponatinib) in chronic myelogenous leukemia (CML), Ariad Pharmaceuticals Inc. is taking advantage of the current public markets to more than double its cash balance. (See BioWorld Today, Dec. 17, 2012.)